Dianthus Therapeutics price target set at $135 by JP Morgan
JP Morgan initiated coverage of Dianthus Therapeutics with an Overweight rating and a $135.00/share price target.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.